Reply to: Delta-Like Ligand 3 Expression Across Lung Neuroendocrine Subtypes: Interpreting Response in Small Cell...

Martin Wermke¹, Valentina Gambardella¹, Yasutoshi Kuboki¹+12

• ¹Martin Wermke, MD, TU Dresden University of Technology, NCT/UCC Early Clinical Trial Unit, Dresden, Germany; Valentina Gambardella, MD, PhD, Department of Medical Oncology, Hospital Clínico Universitario, INCLIVA Biomedical Research Institute, University of Valencia, Valencia, Spain; Yasutoshi Kuboki, MD, PhD, Department of Experimental Therapeutics, National Cancer Center Hospital East, Kashiwa, Japan; Enriqueta Felip, MD, PhD, Department of Oncology, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, pain; Miguel F. Sanmamed, MD, PhD, Department of Oncology, Clínica Universidad de Navarra, Pamplona, Spain; Olatunji B. Alese, MD, Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA; Cyrus M. Sayehli, MD, Interdisciplinary Study Center with ECTU, Medical Clinic and Polyclinic II of the University Hospital, Würzburg, Germany; Edurne Arriola, MD, PhD, Department of Medical Oncology, Hospital del Mar-CIBERONC (Centro de Investigación Biomédica en Red de Oncología), Cancer Research Program, IMIM (Institut Hospital del Mar d'Investigacions Mèdiques), Barcelona, Spain; Jürgen Wolf, MD, Center for Integrated Oncology, University Hospital of Cologne, Cologne, Germany; Liza C. Villaruz, MD, Division of Hematology/Oncology, UPMC Hillman Cancer Center, Pittsburgh, PA; Julia Bertulis, BSc, Boehringer Ingelheim Pharma GmbH & Co KG, Biberach an der Riß, Germany; Matus Studeny, MD, Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany; Mohamed Bouzaggou, PhD, Boehringer Ingelheim France S.A.S., Reims, France; Xiaoyan Fang, MD, PhD, Boehringer Ingelheim (China) Investment Co, Ltd, Shanghai, China; and Daniel Morgensztern, MD, Washington University School of Medicine, St Louis, MO.